AR073513A1 - Orto - aminoanilidas para el tratamiento del cancer - Google Patents
Orto - aminoanilidas para el tratamiento del cancerInfo
- Publication number
- AR073513A1 AR073513A1 ARP090103531A ARP090103531A AR073513A1 AR 073513 A1 AR073513 A1 AR 073513A1 AR P090103531 A ARP090103531 A AR P090103531A AR P090103531 A ARP090103531 A AR P090103531A AR 073513 A1 AR073513 A1 AR 073513A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- halogen
- lower alkyl
- nr4r5
- unsubstituted
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Procesos para la obtencion de dichos compuestos y medicamentos que contengan dichos compuestos. Los compuestos poseen actividad antiproliferante y actividad inductora de la diferenciacion y por ello son utiles para el tratamiento de enfermedades, por ejemplo el cáncer de humano o de animales. Reivindicacion 1: Compuestos de formula general (1) en la que R1 es hidrogeno; halogeno; alquilo inferior, sin sustituir o sustituido una o varias veces por halogeno; cicloalquilo; ciano; alcoxi inferior; R2 es un resto de formula (2), en el que R3 es un anillo heterociclilo de 3-10 eslabones, sin sustituir o sustituido una o varias veces por halogeno, alquilo inferior, hidroxi, -C(O)-alquilo inferior, =O o NR4R5; o es NR4R5; R4/R5 con independencia entre sí son hidrogeno o alquilo inferior; n es el numero 0, 1, 2 o 3, y cuando n = 0, R3 deberá ser un anillo heterociclilo de 3-10 eslabones conectado a través de un átomo de carbono; X es C o N; y las sales, mezclas racémicas, enantiomeros, isomeros opticos o formas tautomeras farmacéuticamente activas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164509 | 2008-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073513A1 true AR073513A1 (es) | 2010-11-10 |
Family
ID=41716278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103531A AR073513A1 (es) | 2008-09-17 | 2009-09-15 | Orto - aminoanilidas para el tratamiento del cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8202866B2 (es) |
| EP (1) | EP2334658A2 (es) |
| JP (1) | JP2011526936A (es) |
| KR (1) | KR20110043767A (es) |
| CN (1) | CN102149678A (es) |
| AR (1) | AR073513A1 (es) |
| AU (1) | AU2009294668A1 (es) |
| BR (1) | BRPI0918508A2 (es) |
| CA (1) | CA2734349A1 (es) |
| IL (1) | IL210066A0 (es) |
| MX (1) | MX2011002574A (es) |
| TW (1) | TWI378093B (es) |
| WO (1) | WO2010031708A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| EP3524324A1 (en) | 2011-02-28 | 2019-08-14 | BioMarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8781041B2 (en) * | 2012-07-31 | 2014-07-15 | Hewlett-Packard Development Company, L.P. | Reducing noise in a sequence of data by linear and non-linear estimation |
| KR20150132345A (ko) | 2013-03-15 | 2015-11-25 | 바이오마린 파머수티컬 인크. | Hdac 저해제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1643264A1 (de) * | 1967-12-20 | 1971-06-09 | Basf Ag | Verfahren zur Herstellung von Aminoaniliden |
| IT1033046B (it) | 1970-10-31 | 1979-07-10 | Finotto Martino | Procedimento di fabbricazione di benzimidazoli sostituiti |
| AU2002327627B2 (en) * | 2001-09-14 | 2006-09-14 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2635210A1 (en) | 2006-01-12 | 2007-08-02 | Merck & Co., Inc. | Hydroxyalkylarylamide derivatives |
| WO2007100657A2 (en) | 2006-02-28 | 2007-09-07 | Merck & Co., Inc. | Inhibitors of histone deacetylase |
| JP2010513326A (ja) * | 2006-12-19 | 2010-04-30 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ |
| WO2008087514A2 (en) * | 2007-01-17 | 2008-07-24 | Orchid Research Laboratories Limited | Hdac inhibitors |
| EP2238103A1 (en) | 2008-01-29 | 2010-10-13 | F. Hoffmann-La Roche AG | Novel n-(2-amino-phenyl)-amide derivatives |
| WO2009138338A1 (en) * | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Novel n-(2-amino-phenyl)-acrylamides |
| JP2011150917A (ja) * | 2010-01-22 | 2011-08-04 | Nippon Soken Inc | ガス拡散層およびそれを備える燃料電池 |
-
2009
- 2009-08-19 US US12/543,527 patent/US8202866B2/en not_active Expired - Fee Related
- 2009-09-07 KR KR1020117006073A patent/KR20110043767A/ko not_active Application Discontinuation
- 2009-09-07 BR BRPI0918508A patent/BRPI0918508A2/pt not_active IP Right Cessation
- 2009-09-07 JP JP2011517178A patent/JP2011526936A/ja active Pending
- 2009-09-07 WO PCT/EP2009/061533 patent/WO2010031708A2/en active Application Filing
- 2009-09-07 MX MX2011002574A patent/MX2011002574A/es not_active Application Discontinuation
- 2009-09-07 AU AU2009294668A patent/AU2009294668A1/en not_active Abandoned
- 2009-09-07 CN CN2009801356932A patent/CN102149678A/zh active Pending
- 2009-09-07 EP EP09782677A patent/EP2334658A2/en not_active Withdrawn
- 2009-09-07 CA CA2734349A patent/CA2734349A1/en not_active Abandoned
- 2009-09-15 TW TW098131074A patent/TWI378093B/zh not_active IP Right Cessation
- 2009-09-15 AR ARP090103531A patent/AR073513A1/es not_active Application Discontinuation
-
2010
- 2010-12-16 IL IL210066A patent/IL210066A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI378093B (en) | 2012-12-01 |
| AU2009294668A1 (en) | 2010-03-25 |
| CA2734349A1 (en) | 2010-03-25 |
| IL210066A0 (en) | 2011-02-28 |
| EP2334658A2 (en) | 2011-06-22 |
| US8202866B2 (en) | 2012-06-19 |
| WO2010031708A2 (en) | 2010-03-25 |
| JP2011526936A (ja) | 2011-10-20 |
| CN102149678A (zh) | 2011-08-10 |
| TW201014834A (en) | 2010-04-16 |
| BRPI0918508A2 (pt) | 2015-12-08 |
| KR20110043767A (ko) | 2011-04-27 |
| MX2011002574A (es) | 2011-04-26 |
| US20100069328A1 (en) | 2010-03-18 |
| WO2010031708A3 (en) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073513A1 (es) | Orto - aminoanilidas para el tratamiento del cancer | |
| UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| AR065128A1 (es) | Derivados de 2-aminooxazolinas como ligandos taar1. procesos de obtencion, composiciones farmaceuticas y usos | |
| PA8680701A1 (es) | Derivados de oxindol | |
| ECSP066302A (es) | Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| GT200600429A (es) | Compuestos organicos | |
| UY27665A1 (es) | Nuevos derivados de piridina y pirimidina | |
| UY27666A1 (es) | Nuevos derivados de piridina y quinolina | |
| ECSP045003A (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos. | |
| UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
| EA201070169A1 (ru) | 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы | |
| ECSP066549A (es) | Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| CR8147A (es) | Derivados de pirido 2, 1a-isoquinolina, como inhibidores de dpp-iv | |
| AR075530A1 (es) | Nuevas orto-aminoamidas para el tratamiento del cancer | |
| ECSP088593A (es) | 5-(arilsulfonil)-pirazolopiperidinas | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| UY29615A1 (es) | Compuestos quimicos iv | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| NI200700032A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| PE20091349A1 (es) | Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |